RESEARCH ARTICLE

Risk Assessment of Patients Undergoing Transfemoral Aortic Valve Implantation upon Admission for Post-Interventional Intensive Care and Surveillance: Implications on Short- and Midterm Outcomes

Fadi Al-Rashid1*, Philipp Kahlert1, Friederike Selge1, Heike Hildebrandt1, Polycarpos-Christos Patsalis1, Matthias Totzeck1, Petra Mummel2, Tienush Rassaf1, Rolf Alexander Jánosi1

1 Department of Cardiology of the West-German Heart and Vascular Center Essen, Essen University Hospital, University Duisburg-Essen, Essen, Germany, 2 Department of Neurology, Essen University Hospital, University Duisburg-Essen, Essen, Germany

* fadi.al-rashid@uk-essen.de

Abstract

Background

Several studies have found that standard risk scores inaccurately reflect risk in TAVI cohorts. The assessment of mortality risk upon post-interventional ICU admission is important to optimizing clinical management. This study sought to determine outcomes and factors affecting mortality in patients admitted to the intensive care unit (ICU) after transcatheter aortic valve implantation (TAVI), and to analyze and compare the predictive values of SAPS II and EuroSCORE.

Methods and Findings

214 consecutive patients treated with transfemoral TAVI (2006–2012) admitted to the ICU in an academic tertiary-care university hospital, were included in this retrospective data analysis. The overall 30-day mortality rate was 7%. Non-survivors at 30-days and survivors showed differences in the rates of catecholamine therapy upon ICU admission (93 vs. 29%; p<0.001), stroke (20 vs. 1%; p<0.001), sepsis (27 vs. 2%; p<0.001), kidney injury (83 vs. 56%; log-rank p<0.001), catecholamine therapy (88 vs. 61%; log-rank p<0.001) and vascular complications (60 vs. 17%; p<0.001). Mean SAPS II score and predicted mortality were higher in non-survivors (38.1 ± 7.0 vs. 29.9 ± 6.2; p<0.001 and 23.1 ± 11.7 vs. 10.5 ± 8.2; p=0.001, retrospectively), whereas the logistic EuroSCORE could not discriminate between the groups (p = 0.555). Among the biochemical parameters, the maximum values of creatinine, procalcitonin, and troponin I during the first 48 h after ICU admission were significantly higher in non-survivors. Multivariate analysis of baseline characteristics and complications associated with two-year mortality showed no significant results.
Conclusions

The SAPS II is a good tool for estimating ICU mortality immediately after performing the TAVI procedure and provides valuable information for other known predictors of mortality.

Introduction

Transcatheter aortic valve implantation (TAVI) has become an established treatment option for inoperable patients with severe symptomatic aortic valve stenosis and is a valuable option for high-risk patients [1,2]. Approximately 30% of all aortic valve procedures in Germany are currently performed via this approach [3]. However, despite recent advances, TAVI continues to be associated with a non-negligible risk of complications such as stroke, acute kidney injury (AKI), vascular complications, or cardiac arrhythmias [4,5].

The postoperative treatment of the TAVI patients, who are usually old and present with various comorbidities, presents a new challenge for intensive care specialists. Although numerous studies have addressed perioperative anaesthetic management [6], little is known about the risk factors that lead to a longer intensive care unit (ICU) stay, which is often associated with higher mortality [7,8]. Several factors, such as the need for invasive respiratory support or catecholamine administration, are generally associated with a poorer survival rate during an ICU stay [9,10]. The impact of these factors on mid-term outcomes in TAVI patients has previously not been evaluated.

Estimation perioperative risk and mortality significantly influences the therapeutic strategy used in patients with symptomatic severe aortic valve stenosis. Several studies have found that standard risk scores (e.g., the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE), inaccurately reflect the risk in TAVI cohorts [11,12]. The assessment of mortality risk greatly influences post-interventional admission to the ICU in order to provide an optimized clinical management. The Simplified Acute Physiology Score (SAPS) II is one of the most common scores used to predict mortality and to discriminate between different patient populations [13,14] in the ICU. SAPS II has not been used for the assessment of mortality in TAVI patients admitted to the ICU for post-interventional surveillance and care, while the predictive impact of SAPS II in comparison to the EuroSCORE in this patient population is not yet known.

Materials and Methods

Patient Population

We retrospectively analysed a consecutive cohort of 214 inoperable and high-risk patients with severe symptomatic aortic stenosis, who underwent transfemoral TAVI and were monitored post-procedurally in our interdisciplinary medical 22-bed ICU between January 2006 and March 2012. Patients who died during the procedure or were monitored post-procedurally on one of the other five ICUs in our hospital were excluded from the analysis (due to limited availability of complete datasets). The local ethics committee of the University of Duisburg-Essen approved this retrospective analysis (No. 15-6311-BO). Patient records were de-identified and analysed anonymously.

Patients with symptomatic severe aortic valve stenosis were considered for TAVI if they had a logistic EuroSCORE ≥ 20% or surgery was considered to involve excessive risk due to comorbidities and other risk factors not reflected by the logistic EuroSCORE (e.g., frailty,
The indication for TAVI in the individual patient was decided upon by consensus of the multidisciplinary Heart Team, which included cardiologists, cardiac surgeons, and physicians from other disciplines whenever needed, according to current guidelines [2].

Patients were excluded from transfemoral TAVI if the following conditions were observed: unsuitable anatomy, unprotected left main coronary disease, recent myocardial infarction or cerebrovascular event, sepsis or active endocarditis, left ventricular or atrial thrombus, active peptic ulcer, or bleeding diathesis.

For our analysis, we divided our cohort into two groups: non-survivors, consisting of all patients who died within 30 days after the TAVI procedure, and the survivors.

**TAVI Procedure**

TAVI was performed by a multidisciplinary heart-team in a hybrid operating room using standard techniques [15,16], predominantly under analgosedation [17], with percutaneous femoral artery access and closure [18]. One of two currently CE-approved bioprosthesis (Edwards Sapien [n = 155] and Medtronic CoreValve [n = 59]) was implanted.

All patients were periprocedurally monitored with a six-electrode virtual 12-lead electrocardiogram and pulse oximetry. Additionally, an indwelling urinary catheter was inserted. A radial artery catheter and a triple lumen central venous catheter in the internal jugular vein (under ultrasound guidance) were placed, along with a pulmonary artery balloon catheter and a provisional pacemaker catheter [17].

**Intensive Care Unit**

Study data were obtained from patients who were admitted to the interdisciplinary 22-bed ICU, which covers the neurology clinic and five specialized departments for internal medicine. In this ICU, 12 beds are devoted to internal medicine patients. The nurse-to-patient ratio was 1:3, and the ICU medical team included six doctors (two intensive care specialists, and four fellows in training), who worked in 8–12 h shifts as critical care physicians.

**Intensive Care Management**

All patients were routinely transferred to the ICU after the procedure for post-interventional surveillance and further care for a minimum of 24 hours. Their vital parameters were monitored continuously and special attention was paid to rhythm disturbances, neurological disorders, access site complications, systemic blood pressure, and fluid balance.

The SAPS II and the corresponding predicted mortality rates were calculated based on data collected within the first hour after ICU admission, respectively, as described previously [13,19].

The assessment of cardiac symptoms and mental status required careful observation of the patients for the early detection of signs of acute heart failure or neurological deficits. This assessment was performed three times a day. Vascular access sites and peripheral pulses were monitored for hematoma, pseudoaneurysm, or acute thrombosis (three times a day). To prevent infections, stringent cleaning of vascular access sites and care of the urinary catheter were performed daily. Whenever signs of systemic infection were present, blood and/or urinary cultures were taken and an appropriate antibiotic therapy was initiated.

Laboratory tests were performed upon admission and the subsequent morning, if not indicated otherwise due to complications. These tests included routine blood count for detecting signs of occult bleeding, infection, dual antiplatelet therapy intolerance, or heparin-induced thrombocytopenia, and for the assessment of renal function, which was used to diagnose AKI.
AKI was defined as an absolute increase in serum creatinine level of $\geq 0.3$ mg/dL ($\geq 26.4$ μmol/L), a percentage increase in serum creatinine level of $\geq 50\%$, or a reduction in urine output, defined as $<0.5$ mL/kg/h for more than 6 h within 48 h after TAVI, in accordance with updated VARC criteria [20].

Standard medical therapy included daily unfractionated heparin until mobilization, acetylsalicylic acid (100 mg), and clopidogrel (75 mg) daily. In cases where oral anticoagulation was required (e.g., for atrial fibrillation), patients were treated with clopidogrel and (oral) anticoagulation with substitution of clopidogrel with acetylsalicylic acid after six months to avoid triple anticoagulation therapy.

Statistical Analysis

Data are presented as the mean ± standard deviation if normally distributed or as median and interquartile range for non-normally distributed data. Categorical variables are given as frequencies and percentages. Categorical data were compared between groups using $\chi^2$ - or Fisher’s exact test. Continuous variables were compared using the Student t-test for dependent and independent samples or the Mann–Whitney U and Wilcoxon signed-rank tests. Survival curves were constructed using Kaplan–Meier estimates based on all available data and were compared using a log-rank test. Statistical significance was assumed when the $p$-value $<$ 0.05. Each tool’s discriminatory power was assessed by calculating the area under the receiver operating characteristic curve (AUROC). The cohort was also divided into four quartiles using the maximum value of specific lab-values for further comparison. Additionally, we performed a multivariate analysis of baseline characteristics and procedural results for two-year mortality. For this purpose we utilized a Cox regression model with forward stepwise analysis. Variables related to two-year mortality with a significance level of $P < 0.1$ were used. For this study, these variables included ejection fraction, mean transaortic pressure gradient, pulmonary hypertension, SAPS II, SAPS II predicted mortality, ICU stay, stroke, sepsis, catecholamine therapy, acute kidney injury, cardiopulmonary resuscitation, and maximal levels of creatinine, procalcitonin (PCT), as well as Troponin I.

All analyses were performed using PASW [SPSS] (Version 21.0, IBM SPSS, Chicago, IL, USA). The authors had full access to the data and take responsibility for their integrity. All authors have read and agreed to the manuscript as written.

Results

Patient characteristics

Our study cohort represents a typical transfemoral TAVI population with severe, symptomatic aortic stenosis and high operative risk due to age and comorbidities (Table 1). Compared with 30-day survivors, non-survivors had a lower ejection fraction than did survivors ($39 \pm 15\%$ vs. $48 \pm 13\%$; $p = 0.008$). Notably, preinterventional risk score assessment by the logistic EuroSCORE failed to discriminate between survivors and non-survivors, both at 30 days and two years (see below).

Mortality

The overall 30-day and two-year mortality rates were 7.5% and 22.4%, respectively. The mortality rate of the previously defined “non-survivors” group, which consisted of all patients who died within 30 days after the TAVI procedure, was 7% ($n = 15$). Nearly all of these patients (14 of 15; 93%) died during their in-hospital/ICU stay.
For the patients, who were alive at 30 days after TAVI ("survivors"), the two-year survival was 83%. Acute kidney injury (83% vs. 56%; log-rank \( p < 0.001 \)) as well as catecholamine therapy (88% vs. 61%; log-rank \( p < 0.001 \)) significantly influenced the two-year survival rate (Fig 1).

Kaplan–Meier estimates comparing outcomes between the two types of TAVI prostheses used did not show a significant difference in short- or long-term mortality rates.

### Table 1. Patient Characteristics.

|                        | All patients n = 214 | Survivor n = 199 | Non-Survivor n = 15 | p-value |
|------------------------|----------------------|------------------|---------------------|---------|
| Age [yrs.], mean±SD    | 80 ± 6               | 80 ± 6           | 81 ± 4              | 0.519   |
| Male sex, n (%)        | 88 (41)              | 80 (40)          | 8 (53)              | 0.455   |
| Logistic EuroSCORE [%], mean±SD | 20 ± 12            | 20 ± 12          | 22 ± 16             | 0.555   |
| SAPS II predicted mortality, mean±SD | 11.4 ± 9.1        | 10.5 ± 8.2       | 23.1 ± 11.7         | <0.001  |
| Arterial hypertension, n(%) | 204 (95)          | 190 (95)         | 14 (93)             | 0.124   |
| Hyperlipidaemia, n(%)  | 163 (76)             | 154 (77)         | 15 (100)            | 0.052   |
| Diabetes mellitus, n(%)| 74 (35)              | 70 (35)          | 4 (27)              | 0.405   |
| Obesity, n(%)          | 84 (39)              | 79 (40)          | 5 (33)              | 0.498   |
| Coronary artery disease, n(%) | 155 (72)         | 146 (73)         | 9 (60)              | 0.133   |
| Myocardial infarction <90 days, n(%) | 8 (4)             | 8 (4)            | 0 (0)               | 0.415   |
| Previous percutaneous coronary intervention, n(%) | 80 (37)          | 75 (38)          | 5 (33)              | 0.600   |
| Prior cardiac surgery, n(%) | 31 (15)           | 30 (15)          | 1 (7)               | 0.333   |
| Ejection fraction [%], mean±SD | 48 ± 13           | 48 ± 13          | 39 ± 15             | 0.008   |
| Chronic obstructive lung disease, n(%) | 51 (24)          | 47 (24)          | 4 (27)              | 0.910   |
| Estimated glomerular filtration rate, mean±SD | 50 ± 19          | 51 ± 19          | 47 ± 19             | 0.425   |
| Creatinine [mg/dl], mean±SD | 1.6 ± 1.1         | 1.6 ± 1.1        | 1.8 ± 1.2           | 0.513   |
| Pulmonary hypertension, n(%) | 25 (12)           | 23 (12)          | 2 (13)              | 0.916   |
| Peripheral artery disease, n(%) | 40 (19)          | 33 (17)          | 7 (47)              | 0.007   |
| NYHA functional class, median(range) | 3 (2–4)          | 3 (2–4)          | 3 (2–4)             | 0.356   |
| Aortic valve area [cm²], mean±SD | 0.6 ± 0.2         | 0.6 ± 0.2        | 0.6 ± 0.1           | 0.588   |
| Mean transaortic pressure gradient [mmHg], mean±SD | 45 ± 18          | 46 ± 18          | 37 ± 18             | 0.072   |

SAPS: Simplified Acute Physiology Score, ICU: Intensive care unit, NYHA: New York Heart Association classification.

doi:10.1371/journal.pone.0167072.t001

![Fig 1. Survival](https://example.com/fig1.png) Survival rate, as indicated by the rate of peri-procedural acute kidney injury (A) and to the need for catecholamine adminstration (B).

doi:10.1371/journal.pone.0167072.g001
Postoperative data and Outcome

Transfemoral TAVI was technically successful in all patients, who were transferred to our ICU for post-interventional surveillance and care. The rates of catecholamine therapy upon admission to the ICU (93% vs. 29%; p < 0.001), stroke (20% vs. 1%; p < 0.001), cardiopulmonary resuscitation (60% vs. 6%; p < 0.001), and sepsis (27% vs. 2%; p < 0.001) were significantly higher in non-survivors compared with survivors (Table 2).

Vascular complications occurred in 20% of all patients (60% vs. 17%) and had an impact on both 30-day (21% vs. 4%; p < 0.001) and two-year mortality (35% vs. 19%; p = 0.012) rates.

SAPS II

The mean SAPS II score was higher in the non-survivors than in the survivors (38.1 ± 7.0 vs. 29.9 ± 6.2; p < 0.001). Based upon these scores, the predicted mortality was 23.1 ± 11.7% and 10.5 ± 8.2% p < 0.001, respectively.

In contrast, the logistic EuroSCORE revealed no differences between the groups (22 ± 16% vs. 20 ± 12%; p = 0.555). Interestingly, both scores overestimated the actual mortality. Nevertheless, the SAPS II successfully discriminated between the groups, whereas the logistic EuroSCORE did not.

The SAPS II exhibited a superior discriminatory performance in comparison to the logistic EuroSCORE, with an AUROC of 0.82 (95% CI 0.70–0.93) and 0.51 (95% CI 0.36–0.66), respectively (Fig 2A). Using receiver operating characteristic curve analysis, a cut-off point of 31.5 proved to be a good predictor of mortality, with a sensitivity of 87% and a specificity of 76%. When this cut-off value was applied, the cumulative survival also showed clearly significant differences also at two years (85% vs. 64%; p < 0.001) (Fig 2B).

Laboratory Values

In order to demonstrate the differences between both groups, four laboratory values were evaluated: creatinine, procalcitonin (PCT), brain natriuretic peptide, and troponin I.

| Table 2. Postoperative data. |
|-------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| All patients n = 214          | Survivor n = 199| Non-Survivor n = 15 | p-value |
| ICU stay [days] mean±SD       | 5.1 ± 9.8       | 4.9 ± 9.9       | 8.0 ± 7.0       | 0.223 |
| SAPS II, mean±SD              | 30.6 ± 6.6      | 29.9 ± 6.2      | 38.1 ± 7.0      | <0.001 |
| SAPS II Predicted Mortality, mean±SD | 11.4 ± 9.1      | 10.5 ± 8.2      | 23.1 ± 11.7     | <0.001 |
| Catecholamines upon admission, n(%) | 71 (33)          | 57 (29)         | 14 (93)         | <0.001 |
| Pacemaker Implantation, n(%)  | 30 (14)         | 28 (14)         | 2 (13)          | 0.856  |
| Stroke, n(%)                  | 4 (2)           | 1 (1)           | 3 (20)          | <0.001 |
| CPR, n(%)                     | 20 (9)          | 11 (6)          | 9 (60)          | <0.001 |
| (Re)Intubation, n(%)          | 24 (11)         | 17 (9)          | 7 (47)          | <0.001 |
| AKI, n(%)                     | 45 (21)         | 39 (20)         | 6 (40)          | 0.094  |
| Bleeding, n(%)                | 23 (11)         | 19 (10)         | 4 (27)          | 0.056  |
| Vascular Complications, n(%)  | 43 (20)         | 34 (17)         | 9 (60)          | <0.001 |
| RBCC, mean±SD                 | 0.3 ± 0.5       | 0.3 ± 0.5       | 0.6 ± 0.5       | 0.007  |
| Pneumonia, n(%)               | 11 (5)          | 8 (4)           | 3 (20)          | 0.012  |
| Sepsis, n(%)                  | 8 (4)           | 4 (2)           | 4 (27)          | <0.001 |
| 30day mortality, n(%)         | 15 (7)          | 0 (0)           | 15 (100)        | <0.001 |

**SAPS**: Simplified Acute Physiology Score, **ICU**: Intensive care unit, **CPR**: cardiopulmonary resuscitation, **AKI**: acute kidney injury, **RBCC**: red blood cell count

doi:10.1371/journal.pone.0167072.t002
maximum values of creatinine (2.46 ± 1.24 vs. 1.77 ± 1.16 mg/dL; p < 0.05), PCT (1.44 ± 1.84 vs. 0.51 ± 1.65 ng/mL; p < 0.05) and troponin I (4.46 ± 4.19 vs. 2.02 ± 2.25 ng/mL; p < 0.001) as well as BNP (996.89 ± 828.41 vs. 762.63 ± 963.65 pg/mL; p = 0.347) during the first 48 hours after ICU admission were significantly higher in the non-survivors compared with survivors.

In addition, our total cohort was divided into quartiles according to the maximum value of each biomarker in order to demonstrate the strength of the relationship between their increase and mortality. In this comparison, the upper quartile (with the highest values) had lower survival rates at two years (Fig 3), which was especially pronounced for creatinine (57% vs. 84%; p < 0.001) and PCT (54% vs. 86%; p < 0.001).

Length of ICU stay
The mean ICU stay of our total cohort was 5.1 ± 9.8 days. The ICU stay of the non-survivors was in accordance with the postoperative course (see above), which was, on average, three days longer than that of the survivors (Table 2).

Multivariate Analysis
In the multivariable model all tested variables showed no independent predictive value concerning two-year mortality.

Discussion
This retrospective, single-centre study describes a transfemoral TAVI patient cohort admitted to a non-surgical ICU for post-interventional surveillance and analyses the risk assessment upon ICU admission including its implications for short- and mid-term outcomes.

Transfemoral TAVI has meanwhile become a well-established and standardized procedure with low complication rates. Yet, it appears that there is less focus on and standardization on of post-procedural care, and the post-procedural management seems to vary across centres. Nevertheless, post-procedural care is crucial due to the unique characteristics of TAVI patients,
who are usually old, comorbid and frail. In this setting, risk assessment upon patient admission to the ICU appears of utmost importance for an improved patient management [21].

We found that almost all 30-day non-survivors died during their ICU stay. Although TAVI was successful in all patients, there were wide variations in the immediate post-procedural course of each patient varied widely. The rates of catecholamine therapy upon admission to the ICU, stroke, cardiopulmonary resuscitation, and sepsis were significantly higher in the non-survivors, and vascular complications negatively impacted survival.

Prognostic scores, such as SAPS II are widely used in the ICU setting. However, these scores have not been validated in patients with severe aortic stenosis, or in relation to TAVI procedures. In contrast to the EuroSCORE [22], which is widely used for preoperative risk assessment despite being known to not provide an accurate prediction of mortality in the setting of TAVI, the SAPS II is a good tool for estimating ICU mortality immediately after the TAVI procedure in this high-risk cohort and provides valuable information for other known predictors of mortality such as AKI, PCT, and myocardial injury. Yet, the SAPS II overestimated the rate of mortality in our study population. Although two specific TAVI risk scores have previously been presented [23,24] that improve the clinical decision-making process, both scores have not yet been applied to routine TAVI screening and also can only serve a moderate discriminatory function in the clinic. Therefore, the SAPS II might still be a valuable tool for the

**Fig 3. Laboratory Values.** Kaplan–Meier curve for survival of all consecutive patients undergoing TAVI according to post-procedural levels of creatinine (A), procalcitonin (B), brain natriuretic peptide (C), and troponin (D), comparing the upper quartile [4] with the lower three quartiles [1–3].

doi:10.1371/journal.pone.0167072.g003
identification of patients who are at an increased risk during post-procedural monitoring. In our cohort, mortality predicted by SAPS II showed a distinct and significant difference between the two groups (23.1 ± 11.7% vs. 10.5 ± 8.2%; p < 0.001).

We examined various laboratory values as predictors of outcome in patients with TAVI. A post-interventional increase in troponin I after TAVI involving some type of myocardial injury is a known risk factor for a higher cardiac mortality, according to previous studies [25,26,27]. There are several possible reasons for myocardial injury during TAVI, such as episodes of extreme hypotension, the use of rapid pacing, or coronary embolism during balloon valvuloplasty and valve implantation [28].

A post-interventional increase in creatinine with the development of AKI has already been reported as an important risk factor for 30-day mortality (HR 4.9). Previous studies report the incidence of AKI after TAVI to be between 12% and 28%, which is comparable with the 21% found in our study [29–32]. Patients treated in the ICU after TAVI who are at risk for developing AKI should be observed and treated carefully, since AKI development is multifactorial and every attempt should be made to avoid this complication.

Developing systemic inflammatory response syndrome (SIRS) during cardiac surgery, particularly during cardiopulmonary bypass, is well known [33–35]. Furthermore, SIRS development has also been demonstrated after the TAVI procedures [7]. As PCT has been shown to be the most specific parameter related to the incidence of SIRS [7], we used PCT as a routine parameter for detection. Accordingly, a post-interventional increase in PCT was a strong predictor of 30-day and two-year mortality. Possible reasons for the development of SIRS include the aforementioned efforts to treat myocardial injury or the injury itself (e.g., balloon valvuloplasty, repositioning of prosthesis, rapid pacing) as well as the consequence of vascular complications and/or major bleeding events, as shown by previous studies [7]. Furthermore, the implications of SIRS coinciding with the development of AKI are discussed in several studies that examined inflammation parameters and AKI [7,36,37].

Limitations

This is a single-centre, retrospective observational report with methodology-inherent potential bias that is common for these types of studies. Exemplary of such bias, the length of the ICU stay cannot be considered a valid retrospective endpoint due to the hesitation of clinicians to transfer patients to the regular ward in the initial years of our TAVI experience. Furthermore, patients that were monitored post-procedurally in one of the other five ICUs in our hospital were excluded from the analysis. However, the length of ICU stay and its reduction are the current focus of the consequences of implementing a minimalist, simplified TAVI procedure with excellent outcomes and a reduced use of health care resources. Use of the SAPS II might potentially help to better advise patients that require a prolonged ICU stay.

Although SAPS II is probably the most extensively used score for assessing illness severity in European ICU patients, various studies have reached dissimilar conclusions regarding its predictive value [13]. Furthermore, SAPS II relies on physiological parameters that are recorded within the first 48 h pre- and post-admission and does, thus, not take into account later deterioration.

Conclusions

Post-operative care after TAVI is challenging due to procedural and postprocedural complications that may affect the outcome of the old, comorbid and frail patients. The identification of patients at higher risk of an unfavourable outcome upon admission to the ICU is therefore important in order to optimize the treatment with the inclusion of prevention strategies for
complications such as AKI and SIRS. Hemodynamic management and the rapid recognition of vascular complications are among the main objectives of early postoperative ICU management requiring close postoperative monitoring and close fluid balance monitoring to prevent AKI.

The results of our study confirm that the SAPS II, obtained upon ICU admission, is applicable to TAVI patients and is useful for predicting 30-day mortality with an acceptable level of accuracy, while performing better than the EuroSCORE. Moreover, impaired renal function, the occurrence of AKI, an increase in PCT, and signs of myocardial injury are strong predictors not only of 30-day, but also two-year mortality after TAVI.

The SAPS II, in combination with biochemical markers, can be used for post-interventional risk stratification in the ICU to optimize patient management and provides valuable information in addition to other known predictors of mortality.

Author Contributions

Conceptualization: FA PK RA.
Data curation: FA FS RA.
Formal analysis: FA FS RA.
Investigation: FA FS HH PP MT PM PK TR RA.
Methodology: FA TR RA.
Project administration: FA RA.
Resources: FA FS HH PP MT PM.
Supervision: TR RA.
Validation: FA TR RA.
Visualization: FA FS RA.
Writing – original draft: FA FS TR RA.
Writing – review & editing: FA TR RA.

References

1. Figulla L, Neumann A, Figulla HR, Kahlert P, Erbel R, Neumann T. Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy. A systematic review of current literature. Clin Res Cardiol. Germany; 2011; 100: 265–276. doi: 10.1007/s00392-010-0268-x PMID: 21165626
2. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. England; 2012; 33: 2451–2496. doi: 10.1093/eurheartj/ehs109 PMID: 22922415
3. Hamm CW, Möllmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, et al. The German Aortic Valve Registry (GARY): in-hospital outcome. European Heart Journal. 2014; 35: 1588–1598. doi: 10.1093/eurheartj/ehu381 PMID: 24022003
4. Khatri PJ, Webb JG, Rodés-Cabau J, Femes SE, Ruel M, Lau K, et al. Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. Ann Intern Med. 2013; 158: 35–46. doi: 10.7326/0003-4819-158-1-201301010-00007 PMID: 23277899
5. Eggebrecht H, Schmermund A, Kahlert P, Erbel R, Voigtlander T, Mehta RH. Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): a weighted meta-analysis of 9,251 patients from 46 studies. EuroIntervention. France; 2013; 8: 1072–1080. doi: 10.4244/EIJV8I9A164 PMID: 23134947
6. Ruggeri L, Gerli C, Franco A, Barile L, Magnano di San Lio MS, Villari N, et al. Anesthetic management for percutaneous aortic valve implantation: an overview of worldwide experiences. HSR Proc Intensive Care Cardiovasc Anesth. 2012; 4: 40–46. PMID: 23440259

7. Sinning JM, Scheer AC, Adenauer V, Ghanem A, Hammerstingl C, Schueler R, et al. Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J. England; 2012; 33: 1459–1468. doi: 10.1093/eurheartj/ehs002 PMID: 22285582

8. Ussia GP, Scarabelli M, Mule M, Barbanti M, Cammalleri V, Imme S, et al. Postprocedural management of patients after transcatheter aortic valve implantation procedure with self-expanding bioprosthesis. Catheter Cardiovasc Interv. United States; 2010; 76: 757–766. doi: 10.1002/ccd.22602 PMID: 20506545

9. Martin C, Viviani X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med. 2000.

10. Póvoa PR, Carneiro AH, Ribeiro OS, Pereira AC, Portuguese C-ASSG. Influence of vasopressor agent in septic shock mortality. Results from the Portuguese Community-Acquired Sepsis Study (SACiUCI study). Critical Care Medicine. 2009; 37: 410–416. doi: 10.1097/CCM.0b013e3181958b1c PMID: 19114885

11. Sedaghat A, Sinning JM, Vasa-Nicotera M, Ghanem A, Hammerstingl C, Grube E, et al. The revised EuroSCORE II for the prediction of mortality in patients undergoing transcatheter aortic valve implantation. Clin Res Cardiol. Germany; 2013; 102: 821–829. doi: 10.1007/s00392-013-0596-8 PMID: 23877301

12. Wendt D, Buck T, Janosi RA, Thielmann M, Pui U, Neuhauer M, et al. Results of a propensity score-matched comparison of the Perimount Magna and Mosaic Ultra aortic valve prostheses. J Heart Valve Dis. England; 2009; 18: 703–711. doi: 10.1111/j.1365-2044.2011.06788.x PMID: 21933156

13. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993; 270: 2957–2963. PMID: 8254858

14. Harrison DA, Brady AR, Parry GJ, Carpenter JR, Rowan K. Recalibration of risk prediction models in a large multicenter cohort of admissions to adult general critical care units in the United Kingdom. Critical Care Medicine. 2006; 34: 1378–1388. doi: 10.1097/01.CCM.0000216702.94014.75 PMID: 16557153

15. Grube E, Buellesfeld L, Mueller R, Sauren B, Zickmann B, Nair D, et al. Progress and Current Status of Percutaneou s Aortic Valve Replacement: Results of Three Device Generations of the CoreValve Revalving System. Circulation: Cardiovascular Interventions. 2008; 1: 167–175. doi: 10.1161/CIRCINTERVENTIONS.108.819839 PMID: 20031675

16. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, Munt BI, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation. United States; 2006; 113: 842–850. doi: 10.1161/CIRCULATIONAHA.105.582882 PMID: 16461813

17. Bergmann L, Kahlert P, Eggebrecht H, Frey U, Peters J, Kottenberg E. Transfemoral aortic valve implantation under sedation and monitored anaesthetic care—a feasibility study. Anaesthesia. 2011; 66: 977–982. doi: 10.1111/j.1365-2044.2011.06788.x PMID: 21933156

18. Kahlert P, Al-Rashid F, Plicht B, Konorza T, Neumann T, Thielmann M, et al. Suture-mediated arterial access site closure after transfemoral aortic valve implantation. Catheter Cardiovasc Interv. 2012. doi: 10.1002/ccd.24326 PMID: 22533193

19. Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer P, Campos RA, et al. SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med. 2005; 31: 1345–1355. doi: 10.1007/s00134-005-2763-5 PMID: 16132892

20. Kappetein AP, Head SJ, Generex P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. European Heart Journal. 2012; 33: 2403–2418. doi: 10.1093/eurheartj/ehs255 PMID: 23026477

21. Laubck SB, Wood DA, Achtem L, Baumbusch J, Boone RH, Cheung A, et al. Risk stratification and clinical pathways to optimize length of stay after transcatheter aortic valve replacement. Canadian Journal of Cardiology. 2014; 30: 1583–1587. doi: 10.1016/j.cjca.2014.07.012 PMID: 25475463

22. Roques F, Nashef SA, Michel P, EuroSCORE SG. Risk factors for early mortality after valve surgery in Europe in the 1990s: lessons from the EuroSCORE pilot program. J Heart Valve Dis. 2001; 10: 572–7– discussion 577–8. PMID: 11603595

23. Capodanno D, Barbanti M, Tamburino C, D’Errigo P, Ranucci M, Santoro G, et al. A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. Am J Cardiol. 2014; 113: 1851–1858. doi: 10.1016/j.amjcard.2014.03.014 PMID: 24837264
24. Lung B, Lauénn C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart. BMJ Publishing Group Ltd and British Cardiovascular Society. 2014; 100: 1016–1023. doi: 10.1136/heartjnl-2013-305314 PMID: 24740804
25. Chorianopoulos E, Krumsdorf U, Geis N, Pleger ST, Giannitsis E, Katus HA, et al. Preserved prognostic value of preinterventional troponin T levels despite successful TAVI in patients with severe aortic stenosis. Clin Res Cardiol. 2013. doi: 10.1007/s00392-013-0624-8 PMID: 24096554
26. Rodes-Cabau J, Gutierrez M, Bagur R, De Larochelliere R, Doyle D, Cote M, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol. United States; 2011; 57: 1988–1999. doi: 10.1016/j.jacc.2010.11.060 PMID: 21565636
27. Yong ZY, Wegerinck EMA, Boerlage-van Dijk K, Koch KT, Vis MM, Bouna BJ, et al. Predictors and Prognostic Value of Myocardial Injury During Transcatheter Aortic Valve Implantation. Circulation: Cardiovascular Interventions. 2012; 5: 415–423. doi: 10.1161/CIRCINTERVENTIONS.111.964852 PMID: 22668556
28. Kahlert P, Al-Rashid F, Plicht B, Wild C, Westhöltder D, Hildebrandt H, et al. Myocardial injury during transfemoral transcatheter aortic valve implantation: an intracoronary Doppler and cardiac magnetic resonance imaging study. EuroIntervention. 2015; 11, doi: 10.4244/EIJY15M05_10 PMID: 26013583
29. Aregger F, Wenaweser P, Hellige GJ, Kadner A, Carrel T, Windecker S, et al. Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement. Nephrol Dial Transplant. England; 2009; 24: 2175–2179. doi: 10.1093/ndt/gfp038 PMID: 19211648
30. Bagur R, Webb JG, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, et al. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. European Heart Journal. 2010; 31: 865–874. doi: 10.1093/eurheartj/ehp56 PMID: 20037180
31. Sinning JM, Ghanei M, Steinhauser H, Adenauer V, Hammerstingl C, Nickenig G, et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. JACC Cardiovasc Interv. United States; 2010; 3: 1141–1149. doi: 10.1016/j.jcin.2010.09.009 PMID: 21087770
32. Strauch JT, Schemer MP, Haldenwang PL, Pfister R, Kuhn EW, Madershahan N, et al. Minimally invasive transapical aortic valve implantation and the risk of acute kidney injury. The Annals of Thoracic Surgery. 2010; 89: 465–470. doi: 10.1016/j.athoracsur.2009.09.090 PMID: 20103322
33. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, et al. Systemic inflammatory response syndrome after cardiac operations. The Annals of Thoracic Surgery. 1996; 61: 1714–1720. doi: 10.1016/0003-4975(96)00033-0 PMID: 8651772
34. Diegeler A, Doll N, Rauch T, Haberer D, Walther T, Falk V, et al. Humoral immune response during coronary artery bypass grafting: A comparison of limited approach, “off-pump” technique, and conventional cardiopulmonary bypass. Circulation. 2000; 102: II95–100. PMID: 11082370
35. Sablotzki A, Friedrich I, Mühleng J, Dehne MG, Spillner J, Silber RE, et al. The systemic inflammatory response syndrome following cardiac surgery: different expression of proinflammatory cytokines and procalcitonin in patients with and without multiorgan dysfunctions. Perfusion. 2002; 17: 103–109. PMID: 11958300
36. Bonventre JV, Zuk A. Ischemic acute renal failure: an inflammatory disease? Kidney Int. 2004; 66: 480–485. doi: 10.1111/j.1523-1755.2004.761.2.x PMID: 15253693
37. Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004; 65: 1357–1365. doi: 10.1111/j.1523-1755.2004.00512.x PMID: 15086475